Gujarat Themis Biosyn soars on reporting 36% rise in Q2 net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Gujarat Themis Biosyn is currently trading at Rs. 756.00, up by 17.35 points or 2.35% from its previous closing of Rs. 738.65 on the BSE.
The scrip opened at Rs. 754.95 and has touched a high and low of Rs. 769.00 and Rs. 740.00 respectively. So far 21495 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 5 has touched a 52 week high of Rs. 769.00 on 7-Nov-2022 and a 52 week low of Rs. 317.00 on 02-Mar-2022.
Last one week high and low of the scrip stood at Rs. 769.00 and Rs. 718.10 respectively. The current market cap of the company is Rs. 1115.08 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 0.03% and 24.97% respectively.
Gujarat Themis Biosyn reported results for second quarter ended September 30, 2022.
The company has reported rise of 35.61% in its net profit at Rs 18.70 crore for Q2FY23 as compared to Rs 13.79 crore for the corresponding quarter previous year. Total income of the company increased by 37.28% to Rs 49.09 crore for the quarter under review as compared to Rs 35.76 crore for the same quarter in the previous year.
Gujarat Themis Biosyn Incorporated in 1981 as a joint sector company with GIIC and Chemosyn Commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group.
